Research Article | Open Access | 10.31586/Dermatology.0402.01
Effect of Colchicine on Th1 and Th17 Cytokines, Cytokine Receptors, and Chemokine Gene Expression Profiles in Behçet's Disease
Received November 13, 2018
Revised January 3, 2019
Accepted January 19, 2019
Published February 1, 2019
AbstractObjective: Colchicine has been used in recent years as an effective drug for controlling attacks in Behçet’s disease. In the present study, we investigated expression levels of IL1R, IL2R, IL12RB, IL23R, IL17, CXCR3, CXCR10 and IL8 genes in patients with active and inactive Behçet’s disease. We also evaluated how colchicine use in patients with active and inactive disease affected these genes and evaluated their role in the etiopathogenesis of the disease. Methods: Thirty-five patients who were diagnosed with Behçet’s disease according to the International Working Group criteria (28 with active disease, 7 inactive) and were taking colchicine were enrolled in the study. Twenty healthy subjects were included as a control group. Expression levels of the IL1R, IL2R, IL12RB, IL23R, IL17, CXCR3 ,CXCR10 and IL8, genes were evaluated. Results: Expression levels of CXCR3 and IL23R were significantly lower in patients with active Behcet's disease when compared with the inactive disease and control groups. However, the differences in CXCR3 and IL23R expression between the inactive Behçet’s patient group and the control group were nonsignificant. Expression levels of the other genes did not differ statistically between the active Behçet’s patients, inactive Behçet’s patients, and control subjects. Conclusion: While the expression levels of the CXCR3 and IL23R genes in active Behçet’s patients were statistically lower than controls, there was no statistical difference between active and inactive Behçet’s patients or controls in terms of IL1R, IL2R, IL17, IL12RB, CXCR10 and IL8, gene expression levels. This study may form the basis for further studies to determine the molecular mechanism of colchicine in the treatment of Behçet's disease.
Evereklioglu C. Current concepts in the etiology andtreatment of Behcet disease. Surv Ophthalmol.2005;50:297-350.
Onder M, Gurer MA. The multiple faces of Behcet'sdisease and its aetiological factors. J Eur Acad DermatolVenereol. 2001;15:126-36.
Arca E, Gür AR. Behçet Hastalığı. T Klin J Med Sci.2003;23:261-8.
Doğanavşargill E, Keser G. Behçet Hastalığı. T KlinJ Int Med Sci 2005;1:80-91.
Boyvat A. Behçet hastalığının etiyopatogenezi. T KlinJ Dermatol. 2004;1415-21.
Yıldırım M, et al. Behçet hastalığı patogenezindeki yenilikler Süleyman Demirel Üniversitesi Týp Fakültesi Dermatoloji AD, Isparta DERLEME. 2009, 16(3): 29-34.
Önder M, Gürer MA. Ülkemizde Behçet hastalığı epidemiyolojisi. T Klin J Int Med Sci 2007;3:4-7.
Doğanavşargil E, Keser G, Behçet hastalığı. In:Gümüþdiþ G, Doðanavþargil E, (eds). KlinikRomatoloji, 1. Baskı. İstanbul, Deniz matbaa, 1999;423-39.
Arayssi T.Hamdan A. New insights into the pathogenesis and therapy of Behçet'sdisease. Curr Opin Pharmacol , 2004:4: 183-8.
Ohno S. Ohguchi M. Hirose S., Matsuda H., Wakisaka A., Aizawa H. Closeassociation of HLA-BW51 with Behçet’s disease. Arch Ophthalmol .1982100(9), 1455-58
Öztaş P, et al.Behçet Hastalığı Etyopatogenezi THE ETIOPATHOGENESIS OF BEHCET'S DISEASE Turkiye Klinikleri J Dermatol .2006;16(4):181-5 DERLEME
Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction ofmonocyte derived tumor necrosis factor alpha, interleukin (IL)13- IL-8 and increased neutrophil superoxide generation inBehcet's disease. A comparative study with familial Mediterraneanfever and healthy subjects. J Rheumatol .1993;20:1544-9
Sayinalp N, Ozcebe Ol, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S: Cytokines in Behcet's disease. J Rheumatol 1996;23:321-2.
Öztas MO, Önder M, Gürer MA, Bukan N, Sancak B. Seruminterleukin 18 and tumour necrosis factor-alpha levels are increasedin Behcet's disease. Clin Exp Dermatol 2005;30:61-3.
Erkan Alpsoy Behçet Hastalığı: Etyopatogenezde Güncel Bilgiler. Turk J Dermatol 2013; 7: 41-5.
Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012;11(10):687-98.
Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmun Rev 2012;11(10):699-704.
Habibagahi Z, Habibagahi M, Heidari M. Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet’s dise-ase. Mod Rheumatol 2010;20(2):154-9.
Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behçet’s disease. J Invest Dermatol 2010;130(8):2136- 8. 29.
Akman A, Alpsoy E. Behçet hastalığı: Etyopatogenezde güncel bilgiler. Turkderm 2009;43(.2):32-8.
Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol 2010;29(11):1211-16.
Abbas AK,Lichtman AH. Basic immunology: functions and disorders of the immune system. 2nd ed. Phiadelphia, PA: W.B Saunders Co, Updated edition 2006-2007
Sang Jin Lee.et al.CXCL10/CXCR3 axis is associatedwith disease activity and thedevelopment of mucocutaneouslesions in patients with Behçet’sdiseaseSci Rep. 2017; 7: 14720.Published online 2017 Nov 7. doi: 10.1038/s41598-017-15189-9.
Houman H, Hamzaoui A, Ben Ghorbal I, Khanfir M, Feki M, Hamzaoui K.Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun. 2004 Nov;23(3):267-73.
M. L. Zoler, Updated Behτet's disease recommendations expand biologic treatment. EULAR 2016 Report, 2016.
Sakane T. Takeno M., Suzuki N., Inaba G. (1999): Behçet’s disease. N Engl J Med Oct,21, 341(17), 1284–912.
Akman-Demir G, Serdaroğlu P,Taşcı B. Clinical patterns of neurologicalinvolvement in Behcet’s disease: evaluation of 200 patients. Brain .1999; 122:2171-81.
Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Jiménez Hernández C, Riebeling-Navarro C, Nava Zavala A, et al. Etiopathogenesis of Behcet’s disea-se. Autoimmun Rev .2010;9(4):241-5.
Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med .2004;4 (1):10–20.
Yazici H, Esen F. Mortality in Behçet's syndrome. Clin Exp Rheumatol .2008;265 5:138–-40.
Ertenli S, et al. Synovial fluid cytokine levels in Behcet’s diseaseI. Clinical and Experimental Rheumatology .2001; 19 ( 24): 37-41.
Ozçimen AA ,et al. IL-1 cluster gene polymorphisms in Turkish patients with Behçet's disease. Int J Immunogenet. 2011 Aug;38(4):295-301.
Rubın LA, e tal.The soluble interleukin-2 receptor:biology, function,and clinicalapplication. Ann Intern Med .1990; 113 619-27
Evereklioglu C, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002. 11(2):87-93.
Takeuchi M, Daniel L Kastnera, and Elaine F Remmersa. The immunogenetics of Behçet’s disease: A comprehensive. J Autoimmun. 2015, 64: 137-148.
Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association Study of IL10 and IL23R-IL12RB2 in Iran-ian patients with Behçet’sdisease. Arthritis Rheum (2012) 64: 2761–72. doi:10.1002/art.34437
Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006; 116:1218–1222.
Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol. 2010; 11:41–44.
Chang JT, Shevach EM, Segal BM. Regulation of interleukin (IL)-12 receptor beta2 subunit expression by endogenous IL-12: a critical step in the differentiation of pathogenic autoreactive T cells. J Exp Med. 1999; 189:969–978.
Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R–IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42:703–706
Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R–IL12RB2 regions associated with Behcet’s disease. Nat Genet. 2010;42:698–702.
Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association study of IL10 and IL23R–IL12RB2 in Iranian patients with Behcet’s disease. Arthritis Rheum. 2012;64:2761–2772.
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991;146:3444–451
Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73.
Talaat RM, Ashour ME, Bassyouni IH, Raouf AA. Polymorphisms of interleukin 6 and interleukin 10 in Egyptian people with Behcet’s disease. Immunobiology. 2014;219:573–582.
Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A. 2013;110:8134–8139.
Yu H, Zheng M, Zhang L Li H, Zhu Y, Cheng L, Li L, Deng B, Kijlstra A, Yang P Allergy Clin Immunol. 2017 Feb;139(2):621-627. .Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behçet's disease in Han Chinese. Allergy Clin Immunol. 2017 ;139(2):621-627
Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. Behçet’s syndro-me: a critical digest of the 2013-2014 literature. Clin Exp Rheumatol. 2014;32(84):S112-22.
Ling E, Shubinsky G, Press J. Increased proportion of CD3+CD4-CD8- double-negative T cells in peripheral blood of children with Behcet’s disease. Autoimmun Rev 2007;6(4):237-40.
Emiroglu N, at al. Serum IL-17A in Behçet's disease Postepy Dermatol Alergol. 2015 Oct; 32(5): 358–361.
Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, Huang X, Kijlstra .Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3058-64
Wei Chi, Peizeng Yang, Xuefei Zhu, Yuqin Wang, Lina Chen,Xiangkun Huang, and Xiaoli Liu1,2.Production of interleukin-17 in Behcet’s disease is inhibited by cyclosporin AMol Vis. 2010; 16: 880–886.
Juremalm M,.Chemokine receptor expression by mast cells Nilsson Chem Immunol Allergy. 2005;87:130-44
Houman H Hamzaoui A, Ben Ghorbal I, Khanfir M, Feki M, Hamzaoui K.Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun. 2004 Nov;23(3):267-73.
Fujii H, Haseagawa M, Takehara K, Mukaida N, Sato S.Abnormal expression and chemokine receptors in peripheralblood T lymphocytes from patients with systemic sclerosis. ClinExp Immunol .2002;130:548
Cosmi L, Annuziato F, Galli M, Maggi R, Nagata K,Romagnani S. CRTH2 is the most reliable marker for thedetection of circulating human Th2 and type 2 T cytotoxic cells inhealth and disease. Eur J Immunol 2000;30:2972.
Sallusto F, Lanzavecchia A, Mackay CR. Chemokines andchemokine receptors in T-cell priming and Th1/Th2-mediatedresponses. Immunol Today 1998;19:568.
Sallusto F, Lenig D, Macka CR, Lanzavecchia A. Flexibleprograms of chemokine receptor expression on human polarizedT helper 1 and 2 lymphocytes. J Exp Med 1998;187:875.
Kaplan AP. Chemokines, chemokine receptors and allergy. IntArch Allergy Immunol 2001;124:423.
Kim TW, Chung H, Yu HG.Chemokine expression of intraocular lymphocytes in patients with Behçet uveitis. Ophthalmic Res. 2011;45(1):5-14.
I Gür-Toy G1, Lenk N, Yalcin B, Aksaray S, Alli NSerum interleukin-8 as a serologic marker of activity in Behçet's disease. .Int J Dermatol. 2005 Aug;44(8):657-60
Durmazlar S.P., Ulkar G.B., Eskioglu F., Tatlican S., Mert A., Akgul A. Significance of serum interleukin-8 levels in patients with Behcet’s disease: High level may indicate vascular involvement. Int. J. Dermatol. 2009;48:259–264.
Sadeghi, A,et al. PMCID: PMC5447940Serum Profiles of Cytokines in Behcet’s Disease Alireza Sadeghi,1 Clin Med. 2017 May; 6(5): 49.
Nalbant S., Sahan B., Durna M., Ersanli D., Kaplan M., Karabudak O., Unal M. Cytokine profile in Behcet uveitis. Bratisl. Lek. Listy. 2008;109:551–554.
Bardak Y, Aridogan B.C. The demonstration of serum interleukin-6, interleukin-8, tumor necrosis factor-α, complement and immunoglobulin levels in BDwith ocular involvement. Ocul. Immunol. Inflamm. 2004;12:53–58.
Inanır I et al.Behcet Hastalığında IL-2R, IL-6 ve IL-8 Turkderm 214 2010; 44: 213-5Immunol Invest.
Karadağ R, et al.Comparison of serum levels of IL-6, IL-8, TNF-α, C reactiveprotein and heat shock protein 70 in patients with active orinactive Behcet’s Turk J Med Sci2010; 40 (1): 57-62.
Zouboulis CC ,etal. Adamantiades-Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res. 2000 Jun;292(6):279-84.